21 CFR Part 820 is the US rule that sets the quality system requirements for medical device manufacturers. Since 2 February 2026 it is called the Quality Management System Regulation (QMSR). The old Quality System Regulation (QSR) wrote its own requirements section by section. Part 820 now incorporates ISO 13485:2016 by reference and adds a short list of FDA-specific requirements on top.
FDA published the final rule on 2 February 2024 and gave manufacturers two years to move over. If you already run an ISO 13485 quality system, most of the work is done. The parts that catch teams out are the ones FDA kept for itself, and the records FDA can now ask to see.
QSR vs QMSR: what changed
- The source of the requirements. The QSR had its own sections (820.20 management responsibility, 820.30 design controls, 820.50 purchasing controls and so on). The QMSR withdraws most of them and points to the clauses of ISO 13485:2016 instead.
- The name. Quality System Regulation became Quality Management System Regulation, matching ISO language.
- The records FDA can review. Under the QSR, internal audit reports, supplier audit reports and management review were exempt from FDA inspection. That exemption is gone. FDA has said it intends to review these records from 2 February 2026, and may look at ones created before that date.
- Terms. The QSR's device master record, device history record and design history file are no longer defined terms. The equivalent content lives in ISO 13485 records such as the medical device file and the design and development file.
- What stayed. The scope, some definitions, and a few FDA-specific requirements where FDA judged ISO 13485 not specific enough.
What Part 820 contains now
The rule is short. Subpart A holds the general provisions: scope (820.1), definitions (820.3), the incorporation of ISO 13485 by reference (820.7) and the core requirement to establish and maintain a quality management system (820.10). Subpart B holds two supplemental provisions:
- 820.35, control of records. Builds on ISO 13485 clause 4.2.5 and spells out content FDA wants in specific records, such as complaint and servicing records.
- 820.45, device labeling and packaging controls. Keeps the old QSR labeling controls because ISO 13485 has no equally specific clause: labeling is checked for accuracy before release, and controls must prevent mix-ups.
Read the current text on the eCFR rather than a summary, including ours. The wording of 820.10 matters, because it is where FDA ties the ISO clauses to its other device rules.
Old QSR sections and where they went in ISO 13485
Many procedures and searches still use the old section numbers. This is where each main QSR section now lives. Check the clause text itself before you rewrite a procedure, because the ISO wording is not identical.
- 820.20 management responsibility (quality policy, quality objectives, management review): ISO 13485 clause 5, including 5.3 quality policy, 5.4.1 quality objectives and 5.6 management review.
- 820.22 quality audit: clause 8.2.4, internal audit.
- 820.25 personnel and training: clause 6.2, human resources.
- 820.30 design controls: clause 7.3, design and development.
- 820.40 document controls: clause 4.2.4, control of documents.
- 820.50 purchasing controls: clause 7.4, purchasing.
- 820.70 production and process controls: clause 7.5.1, with 6.3 infrastructure and 6.4 work environment.
- 820.72 inspection, measuring and test equipment: clause 7.6, control of monitoring and measuring equipment.
- 820.75 process validation: clause 7.5.6, validation of processes for production and service provision.
- 820.90 nonconforming product: clause 8.3.
- 820.100 corrective and preventive action (CAPA): clauses 8.5.2 corrective action and 8.5.3 preventive action.
- 820.120 and 820.130 labeling and packaging: kept by FDA in 820.45.
- 820.180 records: clause 4.2.5, plus FDA's own 820.35.
- 820.198 complaint files: clause 8.2.2, complaint handling, plus the record content in 820.35.
- 820.200 servicing: clause 7.5.4, servicing activities, plus 820.35.
QMSR vs ISO 13485: what is different
The QMSR harmonizes FDA's rule with ISO 13485:2016, but the two are not the same document. The QMSR adds FDA's own definitions, the record content in 820.35, the labeling and packaging controls in 820.45, and the link to other FDA rules. Where an FDA definition differs from an ISO term, FDA's definition applies. ISO 13485 on its own does none of that, and a certification body audit is not an FDA inspection.
What happened to 21 CFR 820.30 design controls
Section 820.30 no longer exists in its old form. Design controls now come from ISO 13485 clause 7.3, design and development, which covers the same ground: planning, inputs, outputs, review, verification, validation, transfer, changes and the design and development file. As before, design controls apply to Class II and Class III devices and to the Class I devices FDA lists.
In practice, a design control procedure written for 820.30 usually maps cleanly to clause 7.3. The gaps tend to be in terms, such as design history file versus design and development file. They also show up in clause 7.3.9, control of design and development changes. That clause asks you to assess the effect of a change on product already delivered.
The FDA rules that sit alongside ISO 13485
An ISO 13485 certificate does not make a company QMSR compliant, and it does not replace an FDA inspection. FDA does not issue or accept certificates in place of its own review.
Other device rules still apply next to the QMSR. They include labeling (21 CFR Part 801), unique device identification (21 CFR Part 830), device tracking (21 CFR Part 821) and medical device reporting (21 CFR Part 803). Electronic records and signatures in the quality system are still subject to 21 CFR Part 11; the QMSR did not change that. Check that your procedures cite them where ISO 13485 is silent.
QMSR gap assessment: a practical check
- Procedures. Replace references to QSR sections with ISO 13485 clauses, and keep the FDA-specific ones (820.35, 820.45, Parts 803, 821, 830) where they apply.
- Audit and management review records. Write them on the assumption that an investigator will read them. Findings with no follow-up, or a management review with no decisions, now show up.
- Risk. ISO 13485 asks for a risk-based approach across the quality system, not only in design. Expect questions about how risk shaped supplier controls, software validation and sampling.
- Software used in the quality system. ISO 13485 clause 4.1.6 requires validation of software used in the quality management system, proportionate to risk. FDA's Computer Software Assurance guidance was reissued in February 2026 to align with the QMSR; see CSA and QMSR for medical device software for how the two fit.
- Training. People who learned the QSR section numbers need the new map, or the old numbers will keep appearing in new documents.
Where software can help
Most of the QMSR work is document and process work: procedures, CAPA, complaints, supplier controls and the records FDA can now review. An eQMS implementation project or our own Cybroscape eQMS handles that side. Cybroscape GxP Copilot covers validation of the software and equipment the quality system depends on. Neither replaces the judgement of the people who own the quality system; they shorten the paperwork around it.
Where to go next
Explore Cybroscape GxP Copilot for AI-native validation, Cybroscape TraceDraft for source-traceable clinical documentation, or book a demo to see either on your own data.